tirzepatide and glp-1 Understand GLP-1/GIP Dual Agonist Its Effect on Current Weight Loss Therapy Bumps and humps in the

When bile becomes supersaturated with cholesterol, gallstones precipitate

The added activation of GIP receptors means tirzepatide can enhance the way your body processes sugar and fat

FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions

Drink at least 16 oz of water in the hour before your first alcoholic drink

Protocol phase 2: initiation (weeks 1 through 8) Week 1: Begin tirzepatide at 2.5mg

Sourcing Quality Compounds in Canada Canadians interested in this stack face unique considerations regarding sourcing and legality